vTv Therapeutics (VTVT) Invested Capital (2014 - 2025)

vTv Therapeutics has disclosed Invested Capital across 12 years of filings, most recently posting $70.9 million for Q3 2025.

• In Q3 2025, Invested Capital rose 295.64% year-over-year to $70.9 million; the TTM figure through Sep 2025 stood at $70.9 million (up 295.64% YoY), while the FY2024 annual figure was $14.3 million, up 158.86% from the prior year.
• Invested Capital came in at $70.9 million for Q3 2025 at vTv Therapeutics, up from $14.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $201.5 million in Q4 2021 to a low of -$51.8 million in Q1 2021.
• Average Invested Capital over 5 years is $6.1 million, with a median of -$10.3 million recorded in 2022.
• Year-over-year, Invested Capital slumped 223.77% in 2023 and jumped 295.64% in 2025.
• Over 5 years, Invested Capital stood at $201.5 million in 2021, then sank by 105.11% to -$10.3 million in 2022, then plunged by 136.09% to -$24.3 million in 2023, then jumped by 158.86% to $14.3 million in 2024, then soared by 395.57% to $70.9 million in 2025.
• Per Business Quant data, the three most recent Invested Capital figures were $70.9 million in Q3 2025, $14.3 million in Q4 2024, and $17.9 million in Q3 2024.